Literature DB >> 26113468

Clinical outcomes of multiple chronic total occlusions in coronary arteries according to three therapeutic strategies: Bypass surgery, percutaneous intervention and medication.

Bum Sung Kim1, Jeong Hoon Yang2, Woo Jin Jang3, Young Bin Song2, Joo-Yong Hahn2, Jin-Ho Choi2, Wook Sung Kim4, Young Tak Lee4, Hyeon-Cheol Gwon2, Sang Hoon Lee2, Seung-Hyuk Choi5.   

Abstract

BACKGROUND: Limited data exist regarding clinical outcomes of multiple chronic total occlusions (CTOs) according to therapeutic strategies, coronary artery bypass grafting (CABG), percutaneous coronary intervention (PCI), and medical treatment (MT).
METHODS: From March 2003 to February 2012, a total of 2024 patients with at least one CTO were enrolled in retrospective, single-center registry. 393 patients with at least two CTOs were categorized based on the intention-to-treat principle. Propensity-score matching was performed. The primary outcome was major adverse cardiac and cerebral events (MACCE).
RESULTS: Of 393 patients with multiple CTOs, 169 patients (43%) were referred for CABG, 130 (33%) for PCI, and 94 (24%) for MT. Median overall follow-up duration was 46.5 (interquartile range 22.7 to 74.6) months. After propensity-score matching analysis, CABG had lower rates of MACCE when compared with PCI (HR=0.43, 0.21-0.85, P=0.01) and MT (HR=0.10, 0.04-0.27, P<0.01). Rates of repeat revascularization was significantly lower in CABG, compared with PCI (HR=0.05, 0.01-0.40, P<0.01) and MT (HR=0.01, 0.00-0.54, P=0.02). CABG had similar rates of cardiac death compared with PCI group (HR=0.97, 0.37-2.53, P=0.95), but had significantly lower rates of cardiac death compared with MT (HR=0.24, 0.08-0.75, P=0.01).
CONCLUSIONS: For management of multiple CTOs, MT alone was associated with higher incidence of cardiac death and MACCE compared with CABG. PCI was associated with higher incidence of MACCE, as driven by higher repeat revascularization rate. These findings suggest that CABG might be associated with better clinical outcome and considered as the preferred treatment strategy in patients with multiple CTOs.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Chronic total occlusion; Coronary artery bypass graft; Medication therapy; Percutaneous coronary intervention

Mesh:

Substances:

Year:  2015        PMID: 26113468     DOI: 10.1016/j.ijcard.2015.06.017

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  11 in total

1.  Chemical suppression of specific C-C chemokine signaling pathways enhances cardiac reprogramming.

Authors:  Yijing Guo; Ienglam Lei; Shuo Tian; Wenbin Gao; Karatas Hacer; Yangbing Li; Shaomeng Wang; Liu Liu; Zhong Wang
Journal:  J Biol Chem       Date:  2019-04-25       Impact factor: 5.157

2.  Evaluation of Oxidative Status in Elderly Patients with Multiple Cerebral Infarctions and Multiple Chronic Total Coronary Occlusions.

Authors:  Xia Li; Dianxuan Guo; Youdong Hu; Ying Chen
Journal:  Dis Markers       Date:  2022-06-28       Impact factor: 3.464

Review 3.  Should Chronic Total Occlusion Be Treated With Coronary Artery Bypass Grafting? Chronic Total Occlusion Should Not Routinely Be Treated With Coronary Artery Bypass Grafting.

Authors:  William S Weintraub; Kirk N Garratt
Journal:  Circulation       Date:  2016-05-03       Impact factor: 29.690

4.  Successful treatment of complex coronary chronic total occlusions improves midterm outcomes.

Authors:  Kai-Ze Wu; Ze-Han Huang; Zhi-An Zhong; Hong-Tao Liao; Yi Zhou; Bing-Zheng Luo; Mahesh Anantha-Narayanan; Rami N Khouzam; Aakash Garg; Vladan Vukcevic; Nicholas G Kounis; Bin Zhang
Journal:  Ann Transl Med       Date:  2019-05

5.  Late Survival Benefit of Percutaneous Coronary Intervention Compared With Medical Therapy in Patients With Coronary Chronic Total Occlusion: A 10-Year Follow-Up Study.

Authors:  Taek Kyu Park; Seung Hun Lee; Ki Hong Choi; Joo Myung Lee; Jeong Hoon Yang; Young Bin Song; Joo-Yong Hahn; Jin-Ho Choi; Hyeon-Cheol Gwon; Sang Hoon Lee; Seung-Hyuk Choi
Journal:  J Am Heart Assoc       Date:  2021-03-04       Impact factor: 5.501

6.  Association of β-blocker therapy with long-term clinical outcomes in patients with coronary chronic total occlusion.

Authors:  Jin Kyung Hwang; Jeong Hoon Yang; Ji-Won Hwang; Woo Jin Jang; Young Bin Song; Joo-Yong Hahn; Jin-Ho Choi; Sang Hoon Lee; Hyeon-Cheol Gwon; Seung-Hyuk Choi
Journal:  Medicine (Baltimore)       Date:  2016-07       Impact factor: 1.889

7.  HDAC inhibitor valproic acid protects heart function through Foxm1 pathway after acute myocardial infarction.

Authors:  Shuo Tian; Ienglam Lei; Wenbin Gao; Liu Liu; Yijing Guo; Jeffery Creech; Todd J Herron; Shaoxiang Xian; Peter X Ma; Y Eugene Chen; Yongqing Li; Hasan B Alam; Zhong Wang
Journal:  EBioMedicine       Date:  2018-12-11       Impact factor: 8.143

8.  Percutaneous Coronary Intervention Versus Medical Therapy for Chronic Total Occlusion of Coronary Arteries: A Systematic Review and Meta-Analysis.

Authors:  Ka Hou Christien Li; Ka Hei Gabriel Wong; Mengqi Gong; Tong Liu; Guangping Li; Yunlong Xia; Jeffery Ho; Luis Nombela-Franco; Abhishek C Sawant; Simon Eccleshall; Gary Tse; Vassilios S Vassiliou
Journal:  Curr Atheroscler Rep       Date:  2019-08-09       Impact factor: 5.113

9.  Long term clinical impact of successful recanalization of chronic total occlusion in patients with and without type 2 diabetes mellitus.

Authors:  Chuan-Tsai Tsai; Wei-Chieh Huang; Hsin-I Teng; Yi-Lin Tsai; Tse-Min Lu
Journal:  Cardiovasc Diabetol       Date:  2020-08-01       Impact factor: 9.951

10.  The success of opening concurrent chronic total occlusion lesion to improve cardiac function trial in patients with multi-vessel disease (SOS-moral): Study protocol of a prospective multicenter study.

Authors:  Jinfan Tian; Huijuan Zuo; Lijun Zhang; Mingduo Zhang; Dongfeng Zhang; Min Zhang; Yuan Zhou; Yi He; Hongzhi Mi; Xueyao Yang; Rongchong Huang; Xiantao Song
Journal:  Medicine (Baltimore)       Date:  2020-05-22       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.